Egypt Immuno-Oncology Research Review Issue 4

In this issue:
  -  Nivolumab for relapsed malignant mesothelioma
  -  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA NSCLC
  -  Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma
  -  OS benefit with tebentafusp in metastatic uveal melanoma
  -  First-line pertuzumab + trastuzumab + taxane for HER2-positive breast cancer
  -  Second-line PD-1 inhibitors vs. chemotherapy in advanced oesophageal SCC
  -  VTE risk with immune checkpoint inhibitors
  -  Immune checkpoint inhibitorassociated sarcoidosis
  -  Nivolumab + ipilimumab for rare gynaecological malignancies
  -  Pembrolizumab for persistent, recurrent or metastatic cervical cancer

Download PDF Subscribe